Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab-based treatment response in metastatic colorectal cancer.
Bottom Line: Patients with baseline CEA serum levels below the statistical median of 26.8 ng/mL (group I) were compared with patients with higher CEA levels (group II).The cetuximab-based treatment cohort was analyzed for specificity assessment of CEA to predict the anti-vascular endothelial growth factor effect in mCRC.In an independent cohort of 129 patients treated with cetuximab-based therapy, no association of therapeutic response or PFS with CEA serum levels was found.
Affiliation: Clinical Division of Oncology, Department of Medicine I and Comprehensive Cancer Center, Medical University of Vienna, Austria.Show MeSH
Related in: MedlinePlus
Mentions: Several reports have described that elevated CEA baseline levels might be prognostic.(21,22) Consistent with these results, the current study confirms a prognostic role of baseline CEA levels in mCRC patients treated with anti-VEGF-based therapy. In order to analyze whether baseline CEA serum levels simply reflect high tumor load, resulting in detrimental treatment outcome, a separate cohort of 129 patients who received cetuximab-based chemotherapy was analyzed. Thereby, baseline CEA serum levels (categorized at 26.8 ng/mL) were not associated with either DC (P = 0.281; Fig. 4a) or PFS (P = 0.221; Fig. 4b). However, as expected, CEA was prognostic as the OS in cetuximab-treated patients with higher CEA levels was decreased (median survival 23.4 months for group I vs 16.7 months for group II, P = 0.014; Fig. 4c).
Affiliation: Clinical Division of Oncology, Department of Medicine I and Comprehensive Cancer Center, Medical University of Vienna, Austria.